Filing Details
Akebia Therapeutics, Inc. (NASDAQ:AKBA) filed a Form 8-K with the Securities and Exchange Commission on June 30, 2026, disclosing a material event.
8k filedNASDAQ:AKBA
Akebia Therapeutics, Inc. (AKBA) Reports Material Event to SEC
Filing Details Akebia Therapeutics, Inc. (NASDAQ:AKBA) filed a Form 8-K with the Securities and Exchange Commission on June 30, 2026, disclosing a material event. Market Context…
Market Context
Akebia Therapeutics, Inc.'s stock currently trades at $1.14 with a market capitalization of $347.6M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Akebia Therapeutics, Inc.'s stock.
All SEC filings for Akebia Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AKBA Stock Page
Frequently Asked Questions
Where can I read AKBA's SEC filings?
Browse all filings on our AKBA SEC filings page.
What types of SEC filings does Akebia Therapeutics, Inc. file?
Public companies like Akebia Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.